aibioCelldex Therapeutics CLDX offering news
Top story · Aug 6, 2026 · aibio.space
Celldex holds $717.6 million before phase 3 readout; CFO Sam Martin to retire
An April stock sale lifted cash, and Celldex guides to funding through 2028. Its finance chief of nine years plans to leave by March 31, 2027.
- Ticker
- CLDX
- Listing
- NASDAQ, United States
- Next date
- Late 2026
- Chief executive
- Anthony Marucci (co-founder, president and CEO)
Desk view · Opinion · Updated Oct 22, 2026
Celldex won its phase 3 trials. The full safety data come next
Celldex has strong phase 3 efficacy in chronic hives and the cash to reach a filing. The debate now turns to safety and to how a mast-cell-depleting injection competes with an oral drug. The full safety tables are the next real test.
Read the full desk viewaibio.space Investor Rank · Opinion
9/10 Most positive view
Both chronic hives phase 3 trials hit every major endpoint and cash funds operations through 2028; full safety data and an oral competitor are the open issues.
- Technology
- 2/2
- Odds
- 2/2
- Balance sheet
- 2/2
- Risk
- 1/2
- Momentum
- 2/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Validated in phase 3. Both EMBARQ-CSU trials hit every major endpoint, with complete response rates of about 42% to 46% at week 12 against 9% to 13% on placebo.
- Odds
- Filing odds are high. Drugs that reach a BLA are approved about 90.6% of the time, and Celldex plans its filing in 2027.
- Balance sheet
- Well funded. Cash was $717.6 million at June 30, with guidance to fund planned operations through 2028.
- Main risk
- Safety and competition. KIT-related side effects, and full phase 3 safety tables not yet released, will be scrutinized against an approved oral pill.
- Watch next
- Full data and dermatitis. The detailed phase 3 presentation and late-2026 atopic dermatitis results come next.
Top news on Celldex
- Financings
Celldex holds $717.6 million before phase 3 readout; CFO Sam Martin to retire
An April stock sale lifted cash, and Celldex guides to funding through 2028. Its finance chief of nine years plans to leave by March 31, 2027.
- Financings
Celldex closes $345 million raise and guides to funding through 2028
First-quarter cash was $451.5 million before the April offering. Celldex then expected phase 3 hives data in the fourth quarter of 2026.
Questions investors ask
What is aibio.space's Investor Rank for Celldex Therapeutics?
9 out of 10, our most positive view. Both chronic hives phase 3 trials hit every major endpoint and cash funds operations through 2028; full safety data and an oral competitor are the open issues. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
Did barzolvolimab work in phase 3?
Yes. Celldex said both EMBARQ-CSU1 and EMBARQ-CSU2 met their primary endpoint, change in weekly urticaria activity score at week 12, and every major secondary endpoint. The primary endpoint comparisons had p-values below 0.00001. Source
When will Celldex file for FDA approval of barzolvolimab?
Celldex plans to submit a Biologics License Application to the FDA in 2027. The phase 3 trials continue treatment to 52 weeks. Source
What safety data has Celldex released from the phase 3 hives trials?
Celldex said barzolvolimab was well tolerated with a favorable safety profile through 24 weeks, consistent with phase 2, but the Sept. 22 release gave no adverse event rates. In the phase 2 CSU program, hair color changes, neutropenia and skin hypopigmentation occurred in more than 10% of treated patients. Source
How much cash does Celldex have?
Celldex had $717.6 million in cash, cash equivalents and marketable securities at June 30, 2026. It says that is enough to fund planned operations through 2028. Source
What is CDX-622?
CDX-622 is Celldex's bispecific antibody against soluble stem cell factor and TSLP. In a phase 1 study in healthy volunteers it lowered serum tryptase in a dose-dependent way and was well tolerated, and an asthma proof-of-mechanism study is ongoing. Source
What is the latest Celldex Therapeutics (CLDX) stock news?
Our latest story on Celldex Therapeutics, dated Aug 6, 2026: "Celldex holds $717.6 million before phase 3 readout; CFO Sam Martin to retire". An April stock sale lifted cash, and Celldex guides to funding through 2028. Its finance chief of nine years plans to leave by March 31, 2027. Source
What is Celldex Therapeutics's latest stock offering or financing news?
Our latest financing story, dated Aug 6, 2026: "Celldex holds $717.6 million before phase 3 readout; CFO Sam Martin to retire". An April stock sale lifted cash, and Celldex guides to funding through 2028. Its finance chief of nine years plans to leave by March 31, 2027. Source
How long will Celldex Therapeutics's cash last?
From our story of Aug 6, 2026: The company said that money should fund planned operations through 2028. Source
How much cash does Celldex Therapeutics have?
From our story of Aug 6, 2026: Celldex Therapeutics reported $717.6 million in cash, cash equivalents and marketable securities at June 30, up from $451.5 million at March 31, in its second-quarter report on Aug. 6. Source
What is Celldex Therapeutics's market cap?
We do not publish live share prices. In its annual report, Celldex Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $1.30 billion as of Jun 30, 2025. Source
Is Celldex Therapeutics a smaller reporting company?
SEC records list Celldex Therapeutics, Inc.'s filer category as: Large accelerated filer. Source
Where is Celldex Therapeutics headquartered?
SEC records list its business address as 53 FRONTAGE ROAD, HAMPTON, NJ, 08827. Source
When does Celldex Therapeutics's fiscal year end?
Celldex Therapeutics, Inc.'s fiscal year ends on December 31, per SEC records. Source
What did Celldex Therapeutics last file with the SEC?
Its most recent filing in our record is an 8-K filed 2026-09-22. All of its filings are on SEC EDGAR. Source
Legal and investor matters
Item 3 of the 10-K filed 2026-02-25 (fiscal year 2025) states: "We are not currently a party to any material legal proceedings." This covers that filing date only. Source
- Other
Celldex reports positive Phase 3 results for barzolvolimab in chronic urticaria
Celldex announced on 2026-09-22 topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria. The company said both trials met the primary endpoint and all key secondary endpoints at 12 weeks. Treatment continues to 52 weeks, and the company plans to submit a BLA to the FDA in 2027. The company disclosed the release in an 8-K.
- Governance
Celldex CFO Sam Martin plans to retire around 2027-03-31
Celldex reported that Senior Vice President and Chief Financial Officer Sam Martin notified the company on 2026-07-10 of his plan to retire on or about 2027-03-31. The 8-K was filed on 2026-07-15. It says the company has started a search for a new Chief Financial Officer and that Mr. Martin intends to continue serving through 2027-03-31 or until a successor begins.
- Financing
Celldex prices public offering of 10.3 million shares at $29.00
Celldex entered an underwriting agreement on 2026-04-01 for the sale of 10,345,000 shares of common stock at a public price of $29.00 per share. The underwriters had a 30-day option for up to 1,551,750 additional shares. The company expected net proceeds of approximately $282 million after discounts, commissions and expenses, and the offering was expected to close on or about 2026-04-06.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| Barzolvolimab (EMBARQ-CSU1 and EMBARQ-CSU2) | Chronic spontaneous urticaria | Phase 3, both trials met primary and all major secondary endpoints; BLA planned for 2027 Source |
| Barzolvolimab (EMBARQ-ColdU and -SD) | Cold urticaria and symptomatic dermographism | Phase 3, enrolling Source |
| Barzolvolimab | Atopic dermatitis | Phase 2, enrollment complete; topline data expected late 2026 Source |
| CDX-622 (SCF and TSLP bispecific) | Asthma; expansion planned into allergic rhinitis and food allergy | Phase 1 proof-of-mechanism study in asthma ongoing Source |
| Barzolvolimab | Prurigo nodularis | Phase 2 missed endpoints; study discontinued (July 2026) Source |
Stock chart
SEC filings and registration
- SEC name
- Celldex Therapeutics, Inc.
- CIK
- 744218
- Industry (SIC)
- In Vitro & In Vivo Diagnostic Substances (2835)
- US tickers
- CLDX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 53 FRONTAGE ROAD, HAMPTON, NJ, 08827
- Phone
- 908-200-7500
- Shares outstanding
- 78,529,532 as of 2026-07-29 (10-Q filed 2026-08-06)
- Former names
- AVANT IMMUNOTHERAPEUTICS INC; T CELL SCIENCES INC
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction